Quantifying Early-Stage Lung Adenocarcinoma Progression with a Radiomic Trajectory

Category	Detail
Condition	Early-stage lung adenocarcinoma (esLUAD)
Key Mechanisms	Integration of radiomic and pathological information via deep contrastive learning to quantify tumor progression continuously
Target Population	Patients with early-stage non-mucinous lung adenocarcinoma
Care Setting	Multi-institutional hospital settings with access to CT imaging and pathological analysis

RadioTrace, a deep learning framework, quantifies esLUAD progression beyond conventional pathological grading.
Pseudo-progression score (PPS) predicts tumor phenotypes such as spread through air spaces (STAS), lymph node metastasis (LNM), and survival outcomes.
RadioTrace reveals significant survival heterogeneity within the same pathological grade, addressing limitations of current grading systems.

Use CT imaging combined with radiomic analysis to non-invasively assess tumor progression in esLUAD.
Incorporate continuous radiomic trajectory measures like RadioTrace to complement histopathological grading.

Consider tumor progression scores from radiomic analysis to guide treatment decisions, especially within the same pathological grade.
Use radiomic progression assessment to identify patients at higher risk for metastasis and poor prognosis.

Apply longitudinal CT follow-ups with radiomic trajectory analysis to monitor continuous tumor progression over time.

Recognize limitations of histopathological grading due to sampling bias and interobserver variability.
Be aware that conventional stepped grading may overlook intragrade heterogeneity affecting prognosis and treatment response.

Patients diagnosed with early-stage non-mucinous lung adenocarcinoma undergoing CT imaging and pathological evaluation

Radiomic progression scores can stratify patients by risk and may inform personalized treatment strategies beyond traditional pathological grades.

Combine radiomic and pathological data using validated frameworks like RadioTrace for comprehensive tumor progression assessment.
Use continuous progression metrics rather than discrete pathological grades to capture tumor heterogeneity.
Incorporate radiogenomic correlations to understand molecular underpinnings of tumor progression.
Utilize non-invasive CT-based radiomic analysis to reduce sampling bias inherent in biopsy-based grading.
Implement longitudinal imaging and radiomic analysis for dynamic monitoring of tumor evolution.

Clinical Scorecard: Assessing Progression of Early-Stage Lung Adenocarcinoma Using a Radiomic Trajectory Analysis